Ozen G, et al. - In a US-wide observational rheumatoid arthritis (RA) cohort, patients with RA treated with abatacept vs other biologic (b) disease-modifying antirheumatic drugs (DMARDs) or conventional synthetic (cs) DMARDs were compared regarding the risks of malignancies, infections and autoimmune diseases. Reviewing data from FORWARD, the National Databank for Rheumatic Diseases, researchers identified 1496 patients who initiated abatacept, 3490 patients who initiated another bDMARD and 1520 patients who initiated a csDMARD. Outcomes of this analysis revealed that patients well-tolerated abatacept. It resulted in no overall elevated risk of malignancies, infections or autoimmune diseases when compared with other bDMARDs or csDMARDs.